

07_metabolic_risk – QC report (publication-oriented)

Endpoint definitions:

- GLU120 $\geq$ 140.0 mg/dL (input unit: mg/dL; mmol/L converted $\times 18.0182$)
- TG/HDL > 3.50
- non-HDL $\geq$ 130.0 (same units as TCHOL/HDL)

Global test policy: Fisher for 2x2 with small expected counts; otherwise chi-square (Yates=True for 2x2).

Multiple testing: BH-FDR applied across the 3 endpoints (see risk_summary_table.csv).


Effect estimates: ORs are CRUDE (unadjusted). Adjusted models (age/BMI) should be reported as primary inferential results.

Reference cluster for ORs: 0


Continuous-marker global tests (Kruskal–Wallis; BH-FDR in CSV):

- GLU120: H=1.29, p=0.2564, q=0.9100
- TCHOL: H=0.40, p=0.5288, q=0.9100
- non_HDL: H=0.18, p=0.6717, q=0.9100
- HDL: H=0.16, p=0.6846, q=0.9100
- GLU0: H=0.11, p=0.7415, q=0.9100
- TG_HDL_ratio: H=0.09, p=0.7606, q=0.9100
- LDL: H=0.04, p=0.8351, q=0.9100
- TG: H=0.01, p=0.9100, q=0.9100


Endpoint prevalence by cluster: risk_glu120_ge_thr
chi2_yates p=0.2227, BH-FDR q=0.2655




Crude ORs vs reference (cluster 0): risk_glu120_ge_thr




Endpoint prevalence by cluster: risk_tghdl_gt_thr
chi2_yates p=0.0385, BH-FDR q=0.1154



Crude ORs vs reference (cluster 0): risk_tghdl_gt_thr



Endpoint prevalence by cluster: risk_nonhdl_ge_thr
chi2_yates p=0.2655, BH-FDR q=0.2655



Crude ORs vs reference (cluster 0): risk_nonhdl_ge_thr

